Previous 10 | Next 10 |
Enanta Pharma (NASDAQ: ENTA ): Q2 GAAP EPS of $0.20 beats by $0.29 . More news on: Enanta Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Webcast and Conference Call today at 4:30 p.m. ET Data from Phase 2a RSV program anticipated mid-2019 and Phase 2a NASH program by the end of third quarter of calendar 2019 Royalty revenue for the quarter was $39.6 million Cash and marketable securities totaled $386.7 mil...
ACLS , ADT , APEI , ATO , ATSG , AVD , AVLR , BECN , BOLD , CERS , CHUY , COLD , CRAY , CRZO , CSOD , CTRE , CWK , DDD , DIOD , DVA , EA , EDIT , ENTA , ESE , EVH , EVRI , FANG , FARM , FATE , FG , FLT , FTSI , GHDX , GTES , HALO , HCLP , HUBS , ICHR , ...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal second quarter ended March 31,...
Most developers of therapies to treat nonalcoholic steatohepatitis (NASH) are under modest pressure as investors remain unimpressed with the initial announcements from The International Liver Congress in Vienna. More news on: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Enanta P...
Thinly traded Enanta Pharmaceuticals ( ENTA -2.2% ) is down on light volume following its announcement of preclinical data on its wholly owned programs in HBV and NASH. The results are being presented at The International Liver Congress in Vienna. More news on: Enanta Pharmaceuticals, ...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that new preclinical data from Enanta’s wholly-owned development programs for hepatitis B ...
New preclinical data to be presented on Core inhibitor EDP-514 targeting HBV FXR agonist EDP-305 targeting NASH ASK-1 inhibitors EP-026856 and EP-027315 targeting NASH Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnolog...
The broad market's down move notwithstanding, most companies working on NASH therapies have moved in lockstep with market following Conatus Pharmaceuticals' ( CNAT -56% ) failed Phase 3 study of emricasan. Many times investors perceive that one company's pain is another's gain. More ne...
Soleno Therapeutics (NASDAQ: SLNO ) -10% . More news on: Soleno Therapeutics, Inc., Tencent Music Entertainment Group, Cellectar Biosciences, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Enanta Pharmaceuticals Inc. Company Name:
ENTA Stock Symbol:
NASDAQ Market:
Enanta Pharmaceuticals Inc. Website:
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strate...
2024-05-10 16:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Nuwellis Inc. (NUWE) rose 60.3% to $0.2741 on volume of 66,284,094 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 21.1% to $0.05 on volume of 64,247,106 shares Clearmind Medicine Inc. (CMND) rose 37.6% to $1.61 on volume ...